Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Difelikefalin for CKD‑associated pruritus in hemodialysis patients (China, Phase 3)
CTR20220844Phase 3Completed
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
- Start
- Apr 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Difelikefalin arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in weekly mean of daily 24-hour WI-NRS score at Week 4 (double-blind period). Started Apr 2022; status: completed.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20220844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220844.